Drug
Hydroxycarbamide
Hydroxycarbamide is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (66.7%)
Phase 31 (33.3%)
Trials by Status
recruiting125%
active_not_recruiting125%
completed250%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_3
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT04116502
completedphase_2
SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)
NCT03806452
active_not_recruiting
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study
NCT04707235
completedphase_2
Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.
NCT05470270
Clinical Trials (4)
Showing 4 of 4 trials
NCT04116502Phase 3
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT03806452Phase 2
SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)
NCT04707235
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study
NCT05470270Phase 2
Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4